查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1474876

失智症治疗市场规模、份额、趋势分析报告：按适应症、药物类别、途径、分销管道、地区、细分市场预测，2024-2030

Dementia Treatment Market Size, Share & Trends Analysis Report By Indication (Alzheimer's Disease Dementia, Vascular Dementia), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

失智症治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球失智症治疗市场规模将达到281.1亿美元，2024年至2030年复合年增长率为7.68%。

失智症患者数量的增加、新药的推出以及市场相关人员和研究机构越来越多地参与开发有效的治疗方法是推动市场成长的一些关键因素。根据 Cross River Therapy 2023 年 9 月发布的资料，英国阿兹海默症（AD）盛行率约为每 10 万人 42.70 人，使其成为人均患者数第二高的国家。

政府和非政府组织为支持失智症治疗认识宣传活动和开发新治疗方法的研究活动而采取的有利倡议的增加预计将推动市场成长。例如，2022年2月，麦吉尔大学的失智症教育计画获得了加拿大公共卫生局的资助，并启动了15个计划，以提高人们对该疾病的认识。失智症社区投资 (DCI) 将投资 758,430 美元，支持该大学为成人学习者提供为期 10 週（总计）的 10 个线上数位学习，以传播看护者的认识。

学术研究机构也从事研究活动，例如研究不同类型的失智症和开发有效的治疗方法以减轻整体疾病负担。例如，2024 年 2 月，科罗拉多大学安舒茨医学校区的研究人员发现 Mdm2 蛋白和在临床实验癌症药物 Nutlin 可以预防与阿兹海默症。此外，2023 年 12 月，宾州大学佩雷尔曼医学院的临床前研究表明，Chaperone分子规定的特定蛋白质可以逆转大脑老化和疾病（包括记忆丧失）的征兆。

新兴市场参与者正在与区域参与者和研究机构合作，以提高开发有效和安全的失智症治疗方法的能力。 2021 年 2 月，Exscientia 与牛津大学合作开发阿兹海默症的治疗方法。此外，Eisai和百健（Biogen）合作快速开发失智症的有效治疗方法。这些公司共同开发了 aducanumab 和 lecanemab。两家公司的这些药物均已获得全球主要监管机构的市场核准。

失智症治疗市场报告亮点

  • 由于AD失智症的高盛行率和认证核可药，AD失智症在适应症细分市场中占据主导地位，2023年份额为60.11%。
  • 由于发病率和严重程度不断增加，路易氏体失智症(LBD) 领域预计从 2024 年到 2030 年将以最快的复合年增长率成长。
  • 由于口服和经皮吸收贴片的处方率较高，胆碱酯酶抑制剂细分市场在 2023 年占据最大份额。
  • 由于组合药物组合药物领域的复合年增长率将达到最快。
  • 由于生物製药的引入和有前景的注射药物管道的存在，预计注射药物给药途径部分将在 2024 年至 2030 年实现最快的复合年增长率。
  • 由于该地区疾病盛行率高、市场参与者强大以及报销政策更好等因素，2023年全球市场将由北美主导。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章失智症治疗市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 失智症治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章失智症治疗市场：适应症估计与趋势分析

  • 全球失智症治疗市场：适应症仪表板
  • 全球失智症治疗市场：适应症变化分析
  • 全球失智症治疗市场：按适应症、收益2018-2030 年
  • 阿兹海默症失智症
  • 血管性失智症
  • 路易氏体失智症
  • 额颞叶型失智症（FTD）
  • 帕金森氏症失智症
  • 其他的

第五章失智症治疗市场：药物类别估计和趋势分析

  • 全球失智症治疗市场：药物类别仪表板
  • 全球失智症治疗市场：药物类别波动分析
  • 全球失智症治疗市场，依药物类别，收益2018-2030
  • 胆碱酯酶抑制剂
  • NMDA受体拮抗剂
  • 单胺氧化酶抑制剂
  • 伴随药物
  • 其他的

第六章失智症治疗市场：给药途径预估及趋势分析

  • 全球失智症治疗市场：途径途径仪表板
  • 全球失智症治疗市场：给药途径变化分析
  • 全球失智症治疗市场：依途径、2018-2030 年收益
  • 口服
  • 经皮吸收贴片
  • 注射

第七章失智症治疗市场：通路估算及趋势分析

  • 全球失智症治疗市场：分销通路仪表板
  • 全球失智症治疗市场：分销管道波动分析
  • 全球失智症治疗市场：按分销管道划分，2018-2030 年收益
  • 医院药房
  • 零售药房
  • 网路药房

第八章失智症治疗市场：区域估计和趋势分析

  • 区域仪表板
  • 市场规模、预测/趋势分析，2018-2030
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • Eisai Co., Ltd.
    • Lilly
    • Novartis AG
    • DAIICHI SANKYO COMPANY, LIMITED
    • AbbVie Inc.
    • H. Lundbeck A/S
    • Biogen
    • Cipla Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Viatris Inc.
Product Code: GVR-4-68040-258-5

Dementia Treatment Market Growth & Trends:

The global dementia treatment market size is anticipated to reach USD 28.11 billion by 2030, registering a CAGR of 7.68% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing patient base of dementia, introduction of novel drugs, and increasing involvement of market players and research institutes to develop effective treatment for the disease are some of key factors driving market growth. According to the Cross River Therapy data published in September 2023, the prevalence of Alzheimer's disease (AD) in the UK is around 42.70 cases per 100,000 people, which makes it the country with the second-greatest number of cases per capita.

Increasing favorable initiatives undertaken by government and non-government bodies to support the awareness campaign and research activities to develop novel therapies for dementia treatment are anticipated to fuel market growth. For instance, in February 2022, McGill University's Dementia Education Program initiated 15 projects funded by the Public Health Agency of Canada to increase awareness about the disease. The Dementia Community Investment (DCI) is going to invest USD 758,430 to support the University's Ten Online Modules over Ten Weeks for Adult Learners (TOTAL) eLearning to spread awareness among caregivers.

Academic and research institutes are further involved in research activities to study different types of dementia and development of effective therapeutics to reduce the overall disease burden. For instance, in February 2024, researchers at the University of Colorado Anschutz Medical Campus found that Mdm2 protein with an investigational cancer drug, nutlin, can prevent the destruction of synapses and dendritic spines associated with Alzheimer's disease. Moreover, in December 2023, A preclinical study from the Perelman School of Medicine at the University of Pennsylvania showed that a chaperone molecule formulated specific proteins that can reverse disease signs including aging brain and memory impairment.

Market players are collaborating with regional players and research institutions to increase their capabilities to develop effective and safe therapy for dementia. In February 2021, Exscientia and the University of Oxford tied up to develop therapies for Alzheimer's disease. Moreover, Eisai Co., Ltd. and Biogen partnered to develop effective therapies for dementia earlier. These companies have jointly developed aducanumab and lecanemab. The companies are receiving market approvals for these drugs from key regulatory authorities across the globe.

Dementia Treatment Market Report Highlights:

  • The AD dementia segment dominated the indication segment market with a share of 60.11% in 2023 owing to a high prevalence of AD dementia and approved drugs
  • The Lewy body dementia (LBD) segment is expected to grow at the fastest CAGR from 2024 to 2030 owing to the increasing incidence and severity of the disease
  • The cholinesterase inhibitors segment held the largest share in 2023 owing to high prescription rate of oral and transdermal patches of these drugs
  • The combination drug segment is projected to experience the fastest CAGR from 2024 to 2030 owing to increased effectiveness and adoption of combination drugs
  • The injectables route of administration segment is anticipated to register the fastest CAGR from 2024 to 2030 owing to the introduction of biological drugs and the presence of promising injectable drugs in the pipeline
  • North America dominated the global market in 2023 owing to factors, such as high disease prevalence, presence of strong market players, and better reimbursement policies in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Drug Class
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Indication and drug class outlook
    • 2.2.2. Route of administration and distribution channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Dementia Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of dementia
      • 3.2.1.2. Increasing government funding and awareness programs
      • 3.2.1.3. Surge in R&D activities
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High failure rates of drugs at approval stages
  • 3.3. Dementia Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Dementia Treatment Market: Indication Estimates & Trend Analysis

  • 4.1. Global Dementia Treatment Market: Indication Dashboard
  • 4.2. Global Dementia Treatment Market: Indication Movement Analysis
  • 4.3. Global Dementia Treatment Market by Indication, Revenue 2018 - 2030 (USD Million)
  • 4.4. Alzheimer's Disease Dementia
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Vascular Dementia
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Lewy Body Dementia
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Frontotemporal Dementia (FTD)
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Parkinson's Disease Dementia
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Dementia Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Global Dementia Treatment Market: Drug Class Dashboard
  • 5.2. Global Dementia Treatment Market: Drug Class Movement Analysis
  • 5.3. Global Dementia Treatment Market by Drug Class, Revenue 2018 - 2030 (USD Million)
  • 5.4. Cholinesterase Inhibitors
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. NMDA Receptor Antagonist
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. MAO Inhibitors
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Combination Drug
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Dementia Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Dementia Treatment Market: Route of Administration Dashboard
  • 6.2. Global Dementia Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Dementia Treatment Market by Route of Administration, Revenue 2018 - 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Transdermal Patch
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Injectable
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Dementia Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Global Dementia Treatment Market: Distribution Channel Dashboard
  • 7.2. Global Dementia Treatment Market: Distribution Channel Movement Analysis
  • 7.3. Global Dementia Treatment Market by Distribution Channel, Revenue 2018 - 2030 (USD Million)
  • 7.4. Hospital Pharmacy
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Retail Pharmacy
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Online Pharmacy
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Dementia Treatment Market: Regional Estimates & Trend Analysis by Indication, Drug Class, Route of Administration, and Distribution Channel

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Mexico
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. Eisai Co., Ltd.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Lilly
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Novartis AG
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. DAIICHI SANKYO COMPANY, LIMITED
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. AbbVie Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. H. Lundbeck A/S
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Biogen
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Cipla Inc.
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Sun Pharmaceutical Industries Ltd.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Viatris Inc.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America dementia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 4 North America dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 North America dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 U.S. dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 8 U.S. dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 U.S. dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Canada dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Canada dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Canada dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe dementia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Europe dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Europe dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Europe dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Germany dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Germany dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Germany dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 25 UK dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 UK dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 UK dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 France dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 29 France dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 France dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 France dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Italy dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Italy dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Italy dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Italy dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 37 Spain dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Spain dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Spain dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Denmark dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 41 Denmark dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Denmark dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Denmark dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Sweden dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 45 Sweden dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Sweden dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Sweden dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Norway dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Norway dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Norway dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Norway dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific dementia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Aisa Pacific dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Aisa Pacific dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 China dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 58 China dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 China dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 China dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Japan dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Japan dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 63 Japan dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Japan dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 India dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 66 India dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 67 India dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 India dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 South Korea dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 70 South Korea dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 71 South Korea dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 South Korea dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73 Australia dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 74 Australia dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 75 Australia dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Australia dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Thailand dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 78 Thailand dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 79 Thailand dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Thailand dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Latin America dementia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 82 Latin America dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 83 Latin America dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 84 Latin America dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 Latin America dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Brazil dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 87 Brazil dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Brazil dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Brazil dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Mexico dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 91 Mexico dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 92 Mexico dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Mexico dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 94 Argentina dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 95 Argentina dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 96 Argentina dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Argentina dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 98 MEA dementia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 100 MEA dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 101 MEA dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 MEA dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 South Africa dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 104 South Africa dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 105 South Africa dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 South Africa dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 111 UAE dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 112 UAE dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 113 UAE dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 UAE dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 115 Kuwait dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 116 Kuwait dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 117 Kuwait dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 Kuwait dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Dementia treatment market: market outlook
  • Fig. 14 Dementia treatment competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Dementia treatment market driver impact
  • Fig. 18 Dementia treatment market restraint impact
  • Fig. 19 Dementia treatment market: Indication movement analysis
  • Fig. 20 Dementia treatment market: Indication outlook and key takeaways
  • Fig. 21 Alzheimer's disease dementia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Vascular dementia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Lewy body dementia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Frontotemporal dementia (FTD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Parkinson'skinson disease dementia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Dementia treatment market: Drug class movement analysis
  • Fig. 28 Dementia treatment market: Drug class outlook and key takeaways
  • Fig. 29 Cholinesterase inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 NMDA receptor antagonist market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 MAO inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Combination drug market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Dementia treatment market: Route of administration movement analysis
  • Fig. 35 Dementia treatment market: Route of administration outlook and key takeaways
  • Fig. 36 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Transdermal patch market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Dementia treatment market: Distribution channel movement analysis
  • Fig. 40 Dementia treatment market: Distribution channel outlook and key takeaways
  • Fig. 41 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Global dementia treatment market: Regional movement analysis
  • Fig. 45 Global dementia treatment market: Regional outlook and key takeaways
  • Fig. 46 Global dementia treatment market share and leading players
  • Fig. 47 North America, by country
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. key country dynamics
  • Fig. 50 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Canada key country dynamics
  • Fig. 52 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 UK key country dynamics
  • Fig. 55 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Germany key country dynamics
  • Fig. 57 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 France key country dynamics
  • Fig. 59 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Italy key country dynamics
  • Fig. 61 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Spain key country dynamics
  • Fig. 63 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Denmark key country dynamics
  • Fig. 65 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Sweden key country dynamics
  • Fig. 67 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Norway key country dynamics
  • Fig. 69 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 China key country dynamics
  • Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Japan key country dynamics
  • Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 India key country dynamics
  • Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Thailand key country dynamics
  • Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Korea key country dynamics
  • Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Australia key country dynamics
  • Fig. 82 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Brazil key country dynamics
  • Fig. 85 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Mexico key country dynamics
  • Fig. 87 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Argentina key country dynamics
  • Fig. 89 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 South Africa key country dynamics
  • Fig. 92 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Saudi Arabia key country dynamics
  • Fig. 94 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 UAE key country dynamics
  • Fig. 96 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Kuwait key country dynamics
  • Fig. 98 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Market share of key market players- 2023